Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Poulos C, Kinter E, Yang JC, Bridges JF, Posner J, Gleibner E, Muhlbacher A, Kieseier B. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. Ther Adv Neurol Disord. 2016 Mar;9(2):95-104. doi: 10.1177/1756285615622736.
Layton JB, Hansen MK, Jakobsen CJ, Kshirsagar AV, Andreasen JJ, Hjortdal VE, Rasmussen BS, Simpson RJ, Brookhart MA, Christiansen CF. Statin initiation and acute kidney injury following elective cardiovascular surgery: a population cohort study in Denmark. Eur J Cardiothorac Surg. 2016 Mar;49(3):995-1000. doi: 10.1093/ejcts/ezv246
Maskey MK, Baral KP, Shah R, Shrestha BD, Lang J, Rothman KJ. Field test results of the motherhood method to measure maternal mortality. Ind Med Gaz. 2011 Jan 1;133(1):64-9.
McKenna SP, Whalley D, Doward LC. Which outcomes are important in schizophrenia? Int J Methods Psychiatr Res. 2000;9(1):S58-67.